GPhA Creates Biosimilars Division; Will New Members Follow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pricing fight over hepatitis C treatments is positive ‘bellwether’ for biosimilars, Momenta CEO says.
You may also be interested in...
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At Generics Group
Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.
New Biosimilars Council Head Seeks Insulin Lessons As More Biosimilar Launches Loom
Craig Burton, who replaces the FDLI-bound Christine Simmon, tells the Pink Sheet that fighting rebating practices which harm insulin patients now can pave the way for successful launches of Humira biosimilars next year. Biosimilar markets should not be ‘winner-take-all,’ he says.